Foghorn Therapeutics
Asad Taherbhoy is a seasoned professional in drug discovery with extensive experience in various roles across notable organizations. Currently serving as the Director of Drug Discovery at Foghorn Therapeutics, Inc., Asad has held positions including Principal Scientist and Senior Scientist. Prior experience includes roles as Scientist II and Scientist in Lead Discovery at Nurix, Inc., and a Post-doctoral Fellow in Early Discovery Biochemistry at Genentech. Asad's early career included a Post-doctoral Fellowship and Graduate Student role at St. Jude Children's Research Hospital, contributing to a robust background in the field.
This person is not in any teams
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.